Pfizer CEO has said that an oral drug to treat novel coronavirus could be ready by the end of the year. Pfizer-BioNTech's coronavirus vaccine has been used in various European countries and the United States and has a very high efficacy as compared to its competitors.

Pfizer CEO says oral drug to treat coronavirus could be ready by end of 2021

The CEO of Pfizer Albert Bourla says that there is likely a need for a third dose of booster shot somewhere between 6 and 12 months and then form there will be annual revaccination but all of that needs to be confirmed. Health official says the emergence of the new variant is the primary reason.

Pfizer CEO Albert Bourla raises possibility of 'annual revaccination '

As the United Kingdom began administering people with the Pfizer-BioNTech vaccine, the World Health Organization(WHO) said the "effects of the vaccines in providing some kind of immune barrier is still far off.

Effects of the vaccine in providing 'immune barrier' is still far off: WHO

Pfizer Inc's CEO Albert Bourla has said that the company is "not certain" if those who receive its vaccine will be able to transmit the coronavirus to others, just one day after the UK became the first to approve the inoculation.

Pfizer CEO 'not certain' if coronavirus vaccine will prevent transmission

pfizer-ceo

Pfizer Ceo, News on Pfizer Ceo, stories on Pfizer Ceo, articles on Pfizer Ceo, Pfizer Ceo stories at Wion, Pfizer Ceo news, Pfizer Ceo latest news

pfizer ceo

Pfizer CEO says oral drug to treat coronavirus could be ready by end of 2021

Pfizer CEO Albert Bourla raises possibility of 'annual revaccination '

Effects of the vaccine in providing 'immune barrier' is still far off: WHO

Pfizer CEO 'not certain' if coronavirus vaccine will prevent transmission